Dr. Mohammed Quadri is a physician, investor, and Founder of GrowQ360, a venture-to-adoption platform focused on healthcare AI and digital health. His work sits at the intersection of clinical care, capital, and real-world deployment, with a focus on accelerating adoption within health systems. He works closely with clinicians, operators, and innovators to bridge the gap between innovation and scalable implementation, particularly in high-friction areas such as patient access, clinical workflows, and revenue cycle optimization.

​Michael Ringel is Chief Operating Officer at Life Biosciences, a biotech company focused on partial epigenetic reprogramming to reverse age-related diseases. He is on the Boards of Hevolution Foundation US and the American Federation for Aging Research. Prior to working at Life Bio, Michael was Managing Director and Senior Partner at BCG, where he worked for 25+ years. Michael has a B.A. summa cum laude in biology from Princeton University, a Ph.D. in biology from Imperial College and a J.D. cum laude from Harvard Law School.

Mari Heghinian, Founder, Seran LLC | VP of Science & Strategic Partnerships, SkyMedAI. She is experienced healthcare technology and clinical research leader specializing in clinical development/execution, AI-driven digital health, and strategy. Extensive experience in digital health innovation, clinical study design, and execution, with a proven ability to anticipate and mitigate risks while ensuring timely issue resolution and successful outcomes.

Erez Kaminski, CEO and Founder of Ketryx, brings over a decade of experience across the AI, biotech, and energy sectors. He specializes in developing mission-critical applications, ranging from pharmaceutical equipment monitoring to AI-driven medication management. Before founding Ketryx, Erez led AI and Machine Learning for Amgen’s medical device division. Having spent his career helping companies of all sizes build safer, more reliable products, Erez is now using Ketryx to improve patient outcomes and unlock new possibilities for regulated product development through AI.

Amir Lahav is the Founder & CEO of SkyMedAI and a recognized Top Voice in Health AI. Drawing on a distinguished career at Harvard Medical School and Pfizer, Amir serves as a retained Strategic Advisor and Board Member for CXOs, investors, startups, and Pharma leaders. Leveraging battle-tested insights across neurological, rare, and chronic diseases, Amir is dedicated to helping companies turn AI vision into a commercial reality, identify clinical hazards before they become liabilities, and future-proof commercial assets in a rapidly evolving AI landscape. Beyond his advisory work, Amir is the Curator and Chair of the DHAI Summit and the author of The Sixth Algorithm™—an insightful and engaging newsletter exploring what it means to be human in an AI-driven world.

Amir Lahav is a founder of SkyMedAI. He is also a Clinical Scientist, Strategic Advisor, and Global Thought Leader at the forefront of Digital Health, Artificial Intelligence, and Modern Medicine. He is the curator and scientific director of the DHAI Summit. Amir sits on the advisory board of multiple medtech startups and holds strategic consulting roles with leading pharmaceutical companies. During his time at Pfizer, he led the development of wearable tech and remote monitoring solutions for gene therapy trials, primarily in rare diseases. Prior to pharma, he was a PI on numerous clinical trials as a Neurology Faculty and Professor of Pediatrics at Harvard Medical School.